Effect of icotinib combined with xiaoaiping injection on the local control rate and level changes of serum SCCA, MMP-9 and TGF-β1 in patients with advanced non-small cell lung cancer

Abstract

Objective To investigate the effect of icotinib combined with xiaoaiping injection on the local control rate and level changes of serum squamous cell carcinoma antigen (SCCA), matrix metalloproteinase-9 (MMP-9) and transforming growth factor-β1 (TGF-β1) in patients with advanced non-small cell lung cancer. Methods Sixty cases of advanced non-small cell lung cancer were divided according to the different ways of treatment. Thirty cases in the control group were given icotinib, and 30 cases in the study group were given xiaoaiping injection based on the treatment in the control group. The clinical effects, levels of serum SCCA, MMP-9 and TGF-β1, adverse reactions and quality of life (WHOQOL-100) scores were analyzed and compared between the two groups. Results The clinical effects of the two groups were significantly different(P 0.05). After 2 months of treatment, the WHOQOL-100 scores of mental health, living ability, environmental adaptability and social relationship of the study group were higher than those of the control group, and the differences were significant (P<0.05). Conclusions The effect of icotinib combined with Shenyi capsules on patients with advanced NSCLC is significant. It can significantly improve the local control rate of tumor, reduce the symptoms and levels of serum SCCA, MMP-9 and TGF-β1, and improve the prognosis. Besides, it has high safety. Key words: Icotinib; Xiaoaiping injection; Non-small cell lung cancer; Local control rate of tumor; Squamous cell carcinoma antigen; Matrix metalloproteinase-9; Transforming growth factor-β1